Selective ultrastructural vulnerability in the cuprizone-induced experimental demyelination
- PMID: 23074847
Selective ultrastructural vulnerability in the cuprizone-induced experimental demyelination
Abstract
Background and purpose: It has been reported that multiple sclerosis has four different neuropathological subtypes, and two of them (type III and IV) are characterized by primary oligodendrocyte loss. However, the exact pathomechanism that lead to oligodendrocyte apoptosis in human demyelinating diseases is still elusive. The copper chelator cuprizone induces primary oligodendrocyte apoptosis and consequent demyelination in well defined areas of the mouse brain. Nevertheless, the precise subcellular events that result in oligodendrocyte cell death in the cuprizone model are still unknown. We aimed to study the ultrastructural alterations that might induce oligodendrocyte apoptosis in the cuprizone experimental demyelination model.
Methods: C57BL/6 mice were given cuprizone for two, 21 and 35 days to induce demyelination to investigate early pathological events, and different stages of demyelination. In addition, mice were given cuprizone for 35 days and were allowed to recover for two or 14 days to study early and late remyelination. After the cuprizone treatment, mice were sacrificed and the corpus callosum, the superior cerebellar peduncle, the optic nerve and the sciatic nerve were studied by electron microscopy.
Results: The ultrastructural analysis revealed that cuprizone induced oligodendrocyte apoptosis is accompanied by the formation of giant mitochondria in the affected cells in the corpus callosum and in the superior cerebellar peduncle. Apoptosis of the myelin producing cells was present through the whole cuprizone challenge. Severe demyelination occurred after three weeks of cuprizone administration associated with massive macrophage infiltration and astrocytosis of the demyelinated areas. Axons and neurons remained unaffected.
Conclusion: The formation of giant mitochondria in myelin producing oligodendrocytes is the first pathological sign in the cuprizone experimental demyelination. Mitochondrium pathology in the cuprizone challenge might serve as a useful model to study the pathomechanism of multiple sclerosis subtypes (III and IV) characterized by primary oligodendrocyte degeneration.
Similar articles
-
Experimental demyelination caused by primary oligodendrocyte dystrophy. Regional distribution of the lesions in the nervous system of mice [corrected].Ideggyogy Sz. 2005 Jan 20;58(1-2):40-3. Ideggyogy Sz. 2005. PMID: 15884397
-
The cuprizone model: regional heterogeneity of pathology.APMIS. 2012 Aug;120(8):648-57. doi: 10.1111/j.1600-0463.2012.02882.x. Epub 2012 Feb 24. APMIS. 2012. PMID: 22779688
-
Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model.J Neuroimmunol. 2013 Sep 15;262(1-2):128-31. doi: 10.1016/j.jneuroim.2013.06.012. Epub 2013 Jul 26. J Neuroimmunol. 2013. PMID: 23890807
-
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.Histol Histopathol. 2011 Dec;26(12):1585-97. doi: 10.14670/HH-26.1585. Histol Histopathol. 2011. PMID: 21972097 Review.
-
Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis.Neurosci Biobehav Rev. 2014 Nov;47:485-505. doi: 10.1016/j.neubiorev.2014.10.004. Neurosci Biobehav Rev. 2014. PMID: 25445182 Review.
Cited by
-
Dapsone reduced cuprizone-induced demyelination via targeting Nrf2 and IKB in C57BL/6 mice.Iran J Basic Med Sci. 2022 Jun;25(6):675-682. doi: 10.22038/IJBMS.2022.64993.14310. Iran J Basic Med Sci. 2022. PMID: 35949308 Free PMC article.
-
Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases.Curr Neuropharmacol. 2019;17(2):129-141. doi: 10.2174/1570159X15666170717120343. Curr Neuropharmacol. 2019. PMID: 28714395 Free PMC article. Review.
-
Structural adaption of axons during de- and remyelination in the Cuprizone mouse model.Brain Pathol. 2019 Sep;29(5):675-692. doi: 10.1111/bpa.12748. Epub 2019 Jul 2. Brain Pathol. 2019. PMID: 31106489 Free PMC article.
-
A cord blood monocyte-derived cell therapy product accelerates brain remyelination.JCI Insight. 2016 Aug 18;1(13):e86667. doi: 10.1172/jci.insight.86667. JCI Insight. 2016. PMID: 27699230 Free PMC article.
-
Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination.Mediators Inflamm. 2013;2013:685317. doi: 10.1155/2013/685317. Epub 2013 May 30. Mediators Inflamm. 2013. PMID: 23818742 Free PMC article.